Budget Amount *help |
¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
Clear cell carcinoma of the ovary (CCC) has the worst prognosis among epithelial ovarian cancers because of its chemoresistance. In this study, we tried to develop a new therapy that targets CCC stem cells. We analyzed the gene expression profile of CCC stem cells established by our group and found the high expression of the stem cell marker LGR5. Moreover, we analyzed the molecular mechanisms of the activation of Wnt signaling by the R-spondin-LGR5 axis and found that R-spondin/Wnt stimuli activate Wnt signaling via promoting novel phosphorylation of Axin1. Thus, both antibodies that target the extracellular domain of LGR5 and small molecules that inhibit Axin1 phosphorylation hold promise as novel anti-tumor reagents.
|